Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.

Manali MukherjeeFernando Aleman ParamoMelanie KjarsgaardBrittany SalterGayatri NairNicola LaVigneKatherine RadfordRoma SehmiParameswaran Nair

Published in: American journal of respiratory and critical care medicine (2019)

Weight-adjusted IV reslizumab was superior to fixed-dose SC mepolizumab in attenuating airway eosinophilia in prednisone-dependent patients with asthma, with associated improvement in asthma control. Clinical trial registered with www.clinicaltrials.gov (NCT 02559791).

Keyphrases

clinical trial
chronic obstructive pulmonary disease
lung function
body mass index
weight loss
physical activity
allergic rhinitis
weight gain
body weight
high dose
open label
cystic fibrosis
study protocol
air pollution